Page 47 - Human Use News Today

The CHMP’s opinion, based on three pivotal Phase III trials showing improvement in clear skin, means therapy could be approved within two months.

NEW YORK--(BUSINESS WIRE)--Sep 19, 2023--

European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma U.S. FDA accepts Biologics License Application in first-line advanced ESCC ...

The Nasdaq 100 closed slightly higher on Monday. Investors, meanwhile, focused on some notable insider trades.

Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data Breast and gastric cancers are among most common types of cancer, accounting together for nearly...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Hungarian pharmaceutical company Gedeon Richter's drug Ryeqo for treatment of endometriosis, Richter and Sumitomo Pharma said on Friday, according to a report by state news wire MTI.

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCYS TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization of EirGenix’s biosimilar for trastuzumab for the treatment of patients with HER2-positive breast and metastatic gastric cancers.

Moderna, Inc. (NASDAQ: MRNA) shares are trading lower Monday alongside other vaccine stocks amid a selloff after the sector gained amid ri

The European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended the approval of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.